Company expands strategic focus into one of oncology’s most urgent supportive-care challengesJericho, New York, April 02, 2026 (GLOBE NEWSWIRE) ...

A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer. The Food and Drug Administration (FDA) OKed phase 2b/3 trials to ...

Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, alongside extreme fatigue, anorexia and anemia in ...

Severe weight loss in cancer patients, medically known as cachexia, has long been one of the most devastating and poorly understood complications of the disease. In fact, a new study has shown that it ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

"Our project is innovative in its use of advanced epigenetic techniques combined with a novel preclinical model of PDAC survivorship," Dr. Arneson-Wissink said. "Together, these tools allow us to ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...